Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
In biotechnology, innovation, expertise, entrepreneurship and a wealth of ideas are what is needed. To this end, highly qualified teams are required to work on the ambitious aims and objectives of biotechnology companies – a prerequisite which is certainly present in great depth at Medigene AG.
Around 80 employees work out of our locations in Martinsried near Munich in Southern Germany and in San Diego, USA, developing new and innovative drugs. The teams are all highly qualified, international and come from various different professions.
Doctors, pharmacists, biologists, chemists, engineers and technicians cooperate in the development of active substances and business graduates, lawyers, finance specialists and marketing experts bring the projects to market.
Medigene AG is fortunate in having a balanced mix of talented young experts and technical specialists with impressive career histories. Superbly well educated, they have all contributed their considerable experiences from other companies they have worked with. More than half the staff are academics, and almost a quarter of them have PhDs. In addition to their technical qualifications, they are all distinguished by their ability to work in a team, to communicate well, and by their willingness to quickly integrate into new working areas. To promote technical and personal development, Medigene AG supports its staff in targeted further education and training and encourages attendance at technical conferences and seminars.
FRANKFURT, May 14 (Reuters) - German biotech firm Medigene
has secured a wider remit under a collaboration with U.S. peer
Bluebird Bio on technology that boosts the immune
response to cancer, increasing the pool of potential milestone
payments to $1.5 billion.